|

SYN818 and Olaparib will be administered Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd1

Indications

  • BRCA 1 /2 and / or HRD1
  • Metastatic Solid Tumor1
  • Advanced Solid Tumors1
  • Ovarian Cancer1
  • Breast Cancer1

Other1 trial

Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.